Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ITEOS THERAPEUTICS, INC.

(ITOS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
34.46(c) 35.3(c) 33.26(c) 35.07(c) 34.82(c) Last
163 168 521 074 326 543 337 405 409 123 Volume
-1.94% +2.44% -5.78% +5.44% -0.71% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 190 M - -
Net income 2021 77,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 16,6x
Yield 2021 -
Sales 2022 326 M - -
Net income 2022 154 M - -
Net Debt 2022 - - -
P/E ratio 2022 8,89x
Yield 2022 -
Capitalization 1 228 M 1 228 M -
Capi. / Sales 2021 6,47x
Capi. / Sales 2022 3,77x
Nbr of Employees 74
Free-Float 99,4%
More Financials
Company
iTeos Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of differentiated immuno-oncology therapeutics for patients. The Company leverages its deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. Its pipeline includes... 
More about the company
Ratings of iTeos Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about ITEOS THERAPEUTICS, INC.
12/03INSIDER SELL : Iteos Therapeutics
MT
11/26INSIDER SELL : Iteos Therapeutics
MT
11/11Piper Sandler Adjusts iTeos Therapeutics' Price Target to $42 From $50, Reiterates Over..
MT
11/11Wedbush Lowers ITeos Therapeutics' Price Target to $48 From $52; Outperform Rating Kept
MT
11/10ITEOS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
11/10ITeos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/10ITeos Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
AQ
11/03ITeos to Report Third Quarter 2021 Financial Results on November 10, 2021
AQ
10/18INSIDER SELL : Iteos Therapeutics
MT
10/14INSIDER SELL : Iteos Therapeutics
MT
10/12INSIDER SELL : Iteos Therapeutics
MT
10/05INSIDER SELL : Iteos Therapeutics
MT
09/28INSIDER SELL : Iteos Therapeutics
MT
09/23INSIDER SELL : Iteos Therapeutics
MT
09/21INSIDER SELL : Iteos Therapeutics
MT
More news
News in other languages on ITEOS THERAPEUTICS, INC.
11/11iTeos annonce ses résultats financiers pour le troisième trimestre 2021 et présente l'a..
11/11iTeos gibt Finanzergebnisse für das dritte Quartal 2021 bekannt und informiert über die..
11/11iTeos gibt Finanzergebnisse für das dritte Quartal 2021 bekannt und informiert über die..
11/03iTeos publiera ses résultats financiers pour le troisième trimestre 2021 le 10ánovembre..
11/03iTeos stellt am 10.áNovemberá2021 seine Geschäftsergebnisse für das dritteáQuartalá2021..
More news
Analyst Recommendations on ITEOS THERAPEUTICS, INC.
More recommendations
Chart ITEOS THERAPEUTICS, INC.
Duration : Period :
iTeos Therapeutics, Inc. Technical Analysis Chart | ITOS | US46565G1040 | MarketScreener
Technical analysis trends ITEOS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 34,82 $
Average target price 46,60 $
Spread / Average Target 33,8%
EPS Revisions
Managers and Directors
Michel Detheux President, Chief Executive Officer & Director
Matthew Gall Chief Financial Officer
David L. Hallal Chairman
Joanne Jenkins Lager Chief Medical Officer
Yvonne McGrath Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ITEOS THERAPEUTICS, INC.2.96%1 228
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819